CHICAGO — July 15, 2015 — The global diagnostics industry is welcoming ORGENTEC-Corgenix to the 2015 American Association of Clinical Chemistry (AACC) Clinical Lab Expo in booth #3711. ORGENTEC-Diagnostika completed its acquisition of Corgenix Medical Corporation in March 2015 and is exhibiting for the first time at AACC. The combined specialty diagnostics company boasts a portfolio of more than 350 diagnostic tests, including ELISA, IFA, LFI, IT and immunoblot.
“The AACC conference marks a new and promising beginning for our companies,” said Werner Hofacher, CEO of the combined ORGENTEC-Corgenix. “Both companies are highly innovative with unique offerings that almost perfectly complement each other. Together, we’ll work on our strategic plan to build ORGENTEC-Corgenix into the global industry leader in specialty diagnostics.”
ORGENTEC excels in autoimmune diagnostics with additional capabilities in specialty infectious disease and organ function testing. Corgenix offers an extensive cardiovascular diagnostics portfolio along with autoimmune, organ function and infectious disease testing.
Corgenix has achieved global recognition for its development of the AspirinWorksÒ Test – the world’s only urine-based test for measuring aspirin effect – and for its Ebola and Lassa rapid diagnostic tests developed in collaboration with the Viral Hemorrhagic Fever Consortium.
“We believe in improving global health care through the development of innovative diagnostic tests targeting a range of conditions, and we look forward to expanding our offerings to even more laboratories, hospitals and patients worldwide,” said Hofacher.
According to Hofacher, exhibiting at the AACC Clinical Lab expo enables ORGENTEC-Corgenix to personally demonstrate the value of the combined operation to current and prospective customers and solidify relationships with strategic partners.
ORGENTEC-Corgenix representatives will be available throughout the expo at booth #3711 to discuss capabilities and answer questions about the new company. Several scientific posters in the infectious disease category will be presented by ORGENTEC-Corgenix researchers; consult the AACC 2015 conference program for full details.
Headquartered in Mainz, Germany, with U.S. operations in Broomfield, Colorado, ORGENTEC offers one of the industry’s most comprehensive portfolios in autoimmune diagnostics and cardiovascular diagnostics with additional strengths in infectious disease, inflammatory rheumatic diseases, thrombotic disorders and organ function testing. The company’s products are supported by a global distribution network, and its line of automated instruments for diagnostics and serology enables labs to complete multiple assays and deliver faster results than traditional analyzers. Additionally, ORGENTEC contract develops and manufactures products for key medical and life science companies.
To learn more about this exciting new development in specialty diagnostics, visit us at booth #3711. For more information on ORGENTEC, visit www.ORGENTEC.com or call +49 6131 / 9258-0; for more information on Corgenix, visit www.corgenix.com or call 303.457.4345 ext. 180.
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor
Phone: 303-623-1190 x230